poisar

Stocks · News reference

Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal

Vandana Singh

Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HOWLMKGAFMKKGY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brodsky & Smith

    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

    Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).

    PSNLHOWLBZHMKTX
  5. Na

    Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

    Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.

    MKKGYANL
  6. Researchandmarkets.Com

    Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity

    The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

    TMOMKKGYDHRATWST